Global Neonatal Hypoxic-Ischemic Encephalopathy Market – Industry Trends and Forecast to 2030

Global Neonatal Hypoxic-Ischemic Encephalopathy Market, By Symptoms (Breathing Problems, Feeding Problems, Missing Reflexes, Seizures, Low Apgar Scores, Low Or High Muscle Tone, Altered Level of Consciousness), Treatment (Therapeutic hypothermia, Drugs, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End-User (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2030.

Neonatal Hypoxic-Ischemic Encephalopathy Market Analysis and Size

Hypoxic-ischemic encephalopathy (HIE), also known as perinatal asphyxia, neonatal encephalopathy, and birth asphyxia, refers to a type of newborn brain damage caused by limited blood flow and oxygen deprivation. This is defined as a form of brain injury which is basically a broad term used for any harm that a baby experiences at or near the time of birth. The increase in the number of people suffering from neonatal hypoxic-ischemic encephalopathy across the globe acts as one of the major factors driving the growth of the global neonatal hypoxic-ischemic encephalopathy market.

Data Bridge Market Research analyses that the global neonatal hypoxic-ischemic encephalopathy market which was USD 1,040.13 million in 2022, is expected to reach USD 1,911.00 million by 2030, and is expected to undergo a CAGR of 7.9% during the forecast period 2023-2030. “Breathing problems” dominate the symptoms segment of the global neonatal hypoxic-ischemic encephalopathy market owing to growing cases of respiratory problems in neonates. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Neonatal Hypoxic-Ischemic Encephalopathy Market Scope and Segmentation

Market Definition

The global neonatal hypoxic ischemic encephalopathy (NHIE) market refers to the sector focused on the diagnosis, treatment, and management of infants who have experienced oxygen deprivation and subsequent brain injury during or shortly after birth. It encompasses pharmaceutical companies, medical device manufacturers, healthcare providers, research institutions, and regulatory bodies involved in addressing NHIE. The market is driven by the demand for effective interventions to mitigate long-term neurological impairments in affected infants. Factors influencing the NHIE market include research advancements, regulatory policies, healthcare infrastructure, and public awareness of neonatal health issues.

Global Neonatal Hypoxic-Ischemic Encephalopathy Market Dynamics

Drivers

• Rising Awareness and Diagnostic Advances

Increasing awareness among healthcare professionals and the general public about NHIE leadsto improved recognition and diagnosis of the condition. Advances in diagnostic techniques, such as advanced imaging technologies and biomarker identification, contribute to early detection and intervention, driving market growth.

• Research and Development Efforts

Ongoing research and development activities focused on NHIE contribute to the discovery of new therapeutic interventions and treatment modalities. Pharmaceutical companies and research institutions invest in developing neuroprotective agents, novel drug formulations, and innovative therapies, stimulating market growth.

Opportunities

• Advancements in Treatment Options

As research and development efforts continue, there is a possibility of discovering new and improved treatment options for NHIE. This could include novel pharmaceutical interventions, neuroprotective therapies, or innovative approaches such as stem cell therapy or gene therapy. These advancements could lead to more effective and targeted treatments for NHIE, potentially improving patient outcomes.

• Development of Supportive Technologies

The global NHIE market growth may drive the development of new technologies and medical devices specifically designed for the diagnosis, monitoring, and treatment of neonates with hypoxic ischemic encephalopathy. These technologies could include advanced imaging techniques, wearable devices for continuous monitoring, or specialized equipment for neonatal intensive care units (NICUs). Such innovations can enhance the quality of care provided to affected infants and improve overall outcomes.

Restraints/Challenges

• Hindrance in The Expansion of Neonatal Hypoxic-Ischemic Encephalopathy Market

There are various obstacles that may hinder the expansion of the neonatal hypoxic-ischemic encephalopathy market. These challenges include limited treatment options, lack of awareness, and costly treatments. These factors can impede market growth and pose barriers for market players in the forecast period of 2023-2030

This global neonatal hypoxic-ischemic encephalopathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global neonatal hypoxic-ischemic encephalopathy market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Neonatal Hypoxic-Ischemic Encephalopathy Market Scope

The global neonatal hypoxic-ischemic encephalopathy market is segmented on the basis of symptoms, treatment, mode of administration, distribution channel, end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Symptoms

• Breathing Problems
• Feeding Problems
• Missing Reflexes
• Seizures
• Low Apgar Scores
• Low or High Muscle Tone
• Altered Level of Consciousness

Treatment

• Therapeutic hypothermia
• Drugs
• Other

 Mode of Administration

• Injectable
• Oral
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Neonatal Hypoxic-Ischemic Encephalopathy Market Regional Analysis/Insights

The global neonatal hypoxic-ischemic encephalopathy market is analysed and market size insights and trends are provided by country, symptoms, treatment, mode of administration, distribution channel, and end-user as referenced above.

The countries covered in the global neonatal hypoxic-ischemic encephalopathy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global neonatal hypoxic-ischemic encephalopathy market due to the well-established healthcare infrastructure and increases in drug approvals within the region.

Asia-Pacific is expected to witness high growth during the forecast period 2023-2030 because of the developing health care infrastructure and large patient population in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global neonatal hypoxic-ischemic encephalopathy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global neonatal hypoxic-ischemic encephalopathy Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global neonatal hypoxic-ischemic encephalopathy market. The data is available for historic period 2023-2030.

Competitive Landscape and Global Neonatal Hypoxic-Ischemic Encephalopathy Market Share Analysis

The global neonatal hypoxic-ischemic encephalopathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global neonatal hypoxic-ischemic encephalopathy market.

Some of the major players operating in the global neonatal hypoxic-ischemic encephalopathy market are:

• Eisai Co. Ltd. (Japan)
• Pfizer, Inc. (U.S.)
• Sanofi (France)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• Novartis AG (Switzerland)
• Allergan (Ireland)
• Merz Pharma (Germany)
• Johnson & Johnson Services, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• AbbVie Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Bayer AG (Germany)
• Biogen (U.S.)
• AstraZeneca (U.K.)
• VTV Therapeutics (U.S.)
• H. Lundbeck A/S (Denmark)
• TauRx Pharmaceuticals Ltd (U.K.)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)